Recent advances of molecular targeted agents: opportunities for imaging.
A number of agents targeting components of pathways and processes critical to neoplastic transformation and progression are ongoing clinical development. Notable successes include imatinib mesylate (STI571, Gleevec) in Chronic Myelogenous Leukemia (CML), and Gastrointestinal Stromal Tumors (GIST) and trastuzumab (Herceptin) in HER2 amplified breast carcinoma. More recently, gefitinib (ZD1839, Iressa) and bortezomib (PS-341, Velcade) have been approved for refractory nonsmall cell lung carcinoma (NSCLC) and multiple myeloma (MM), respectively. In addition, promising results from randomized studies of bevacizumab (Avastin) and cetuximab (IMC-225, Erbitux) have been reported and shortly may lead to their approval for the treatment of colorectal carcinoma (CRC). To what degree the success or failure of these agents has been due to target, the agent, the dose or the selection of patients is uncertain. Certainly, further evaluation of these factors is required to optimize the therapeutic impact of targeted agents and imaging modalities may play a vital role in this process. The purpose of this review is to summarize recent results from trials of selected targeted agents and to suggest roles imaging may play in the further development of these and other targeted agents.
Dancey
Janet E
JE
Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland 20892, USA. danceyj@ctep.nci.nih.gov
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D000068258:Bevacizumab; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D002471:Cell Transformation, Neoplastic / Q000378:metabolism; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy; D003952:Diagnostic Imaging; D005544:Forecasting; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000473:pathology; D000077156:Gefitinib; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008175:Lung Neoplasms; D009101:Multiple Myeloma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D017154:Stromal Cells / Q000187:drug effects / Q000473:pathology; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D001897:Boronic Acids; D010879:Piperazines; D011719:Pyrazines; D011743:Pyrimidines; D011799:Quinazolines; D000068258:Bevacizumab; D000069286:Bortezomib; D000068877:Imatinib Mesylate; D000068878:Trastuzumab; D000068818:Cetuximab; D000077156:Gefitinib